Day: April 28, 2021

PetVivo Awarded Key Biocompatible Stent Patent by the United States Patent and Trademark Office

Written by Customer Service on April 28, 2021. Posted in Public Companies.

PetVivo Holdings, Inc.Key Biocompatible Stent PatentMINNEAPOLIS, MN, April 28, 2021 (GLOBE NEWSWIRE) — PetVivo Holdings, Inc. (OTCQB:PETV) an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices and therapeutics for pets is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued a patent related to the Company’s proprietary encapsulated or coated stent systems. The broad scope of the issued claims in this patent, entitled “Encapsulated or Coated Stent Systems” provides protection for a broad range of proprietary products, including stents coated with PetVivo’s biocompatible coacervate biomaterial. PetVivo’s biomaterial technology and the claims issued in this patent provide comprehensive coverage related to biocompatible...

Industrial Diesel Turbocharger Market to grow at a 8.72% CAGR by 2027 | Market Research Future (MRFR)

Written by Customer Service on April 28, 2021. Posted in Mergers And Acquisitions.

Key companies profiled include Volkswagen AG, Mitsubishi Heavy Industries, Ltd, ABB, Rolls-Royce plc, Toyota Motor Corporation, Cummins Inc, Napier Turbochargers Ltd, Turbo Service International BV, BorgWarner Inc, and Kompressorenbau Bannewitz GmbH., among others. Pune, April 28, 2021 (GLOBE NEWSWIRE) — Industrial Diesel Turbocharger Market Analysis Market Research Future (MRFR) predicts the global industrial diesel turbocharger market to hit USD 5,892.3 million at an 8.72% CAGR from 2020 to 2027 (forecast period). The demand for industrial diesel turbochargers is expected to grow significantly during the forecast period. Rising usages of diesel turbochargers in marine, agricultural equipment, power generation, construction equipment, railways, mining equipment, and other applications drive market demand. Furthermore, the growing...

Red White & Bloom Closes Acquisition of Florida Operations from Acreage Holdings

Written by Customer Service on April 28, 2021. Posted in Mergers And Acquisitions.

TORONTO, April 28, 2021 (GLOBE NEWSWIRE) — Red White & Bloom Brands Inc. (CSE: RWB and OTC: RWBYF) (“RWB” or the “Company”) is pleased to announce that, further to its press release of February 25, 2021, its new subsidiary, RWB Florida LLC, has completed the acquisition of all of the issued and outstanding shares of Acreage Florida, Inc. (“Acreage Florida”) from High Street Capital Partners, LLC (the “Seller”), a subsidiary of Acreage Holdings Inc. (“Acreage”) (CSE: ACRG.A.U; ACRG.B.U) (OTCQX: ACRDF, ACRHF). RWB also completed the acquisition of certain owned and leased real estate assets used in Acreage Florida’s operations (the “Florida Real Estate”). RWB Florida is licensed to operate medical marijuana dispensaries, a processing facility, and a cultivation facility in the state of Florida. The deal also includes the sale...

Driven Brands Holdings Inc. Reports First Quarter Results

Written by Customer Service on April 28, 2021. Posted in Public Companies.

Delivers Positive Same-Store Sales and Strong Operating IncomeRaises Fiscal Year 2021 Guidance CHARLOTTE, N.C., April 28, 2021 (GLOBE NEWSWIRE) — Driven Brands Holdings Inc. (NASDAQ: DRVN) (“Driven Brands” or “the Company”) today reported financial results for the first quarter ended March 27, 2021. For the first quarter, revenue was $329.4 million, an increase of 83% versus the prior year. System-wide sales hit a record $1.0 billion, an increase of 28% versus the prior year, with 37% net store growth and an increase in consolidated same-store sales of 0.5%. Loss per share was $(0.13) for the first quarter, driven by a $(0.23) per share impact from the one-time non-cash loss on debt extinguishment from proceeds associated with the Company’s initial public offering. Adjusted earnings per share2 was $0.19, an increase of 138% versus...

Depression Disconnect: GeneSight® Mental Health Monitor Shows Misunderstanding of Depression and Treatment

Written by Customer Service on April 28, 2021. Posted in Public Companies.

New poll shows 83% of people with depression agree life would be easier if others could understand their depression SALT LAKE CITY, April 28, 2021 (GLOBE NEWSWIRE) — In a new nationwide poll, the GeneSight® Mental Health Monitor found that 83% of people with depression agree that life would be easier if others could understand their depression. Yet, most people who have not experienced depression may not be able to understand the challenges, including its treatment. “Depression is one of the most misunderstood disorders. When people misinterpret patients with depression as ‘lazy’ or ‘dramatic,’ they are vastly underestimating and misunderstanding the debilitating symptoms of major depressive disorder,” said Mark Pollack, M.D., chief medical officer for the GeneSight test at Myriad Genetics. “That is why we are working with the...

uniQure Announces Presentations at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Written by Customer Service on April 28, 2021. Posted in Public Companies.

LEXINGTON, Mass. and AMSTERDAM, The Netherlands, April 28, 2021 (GLOBE NEWSWIRE) — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that five data presentations, of which two are oral presentations, will be delivered at the American Society of Gene and Cell Therapy (ASGCT) Virtual 2021 Annual Meeting being held May 11-14. “Our presentations at ASGCT showcase our gene therapy expertise in hemophilia and Huntington’s disease, as well as advantages of the AAV5 vector in dosing through pre-existing neutralizing antibodies,” stated Ricardo Dolmetsch, Ph.D.president of research and development at uniQure. “In addition, we look forward to presenting preclinical data demonstrating the potential of the miQURE technology used in our...

Editas Medicine to Host Conference Call Discussing First Quarter 2021 Results and Corporate Update

Written by Customer Service on April 28, 2021. Posted in Public Companies.

CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Wednesday, May 5, 2021, at 8:00 a.m. ET to discuss a corporate update and results for the first quarter of 2021.Conference Call & Webcast DetailsDate: Wednesday, May 5, 2021 Time: 8:00 am Eastern TimeToll Free: (844) 348-3801International: (213) 358-0955Conference ID: 7587147Webcast: https://edge.media-server.com/mmc/p/vfqo9b5qThe live webcast of the conference call can also be accessed in the Investors section of Editas Medicine website at https://www.editasmedicine.com/. About Editas MedicineAs a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9...

Orchard Therapeutics Announces Multiple Presentations at the 24th Annual Meeting of the American Society of Gene & Cell Therapy

Written by Customer Service on April 28, 2021. Posted in Public Companies.

Seven abstracts accepted show the potential of HSC gene therapy to transform the treatment of multiple severe rare disorders First peer-reviewed presentation from company’s work in transduction enhancers showcases promise to improve manufacturing efficiency of lentiviral-based gene therapy BOSTON and LONDON, April 28, 2021 (GLOBE NEWSWIRE) — Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced the acceptance of seven abstracts at the 24th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) taking place virtually from May 11-14. Accepted abstracts include clinical data from several of its hematopoietic stem cell (HSC) gene therapy programs, including: OTL-203, being investigated for the treatment of mucopolysaccharidosis type I (MPS-I), and OTL-101, being investigated for the...

Trillium Therapeutics Announces Dosing of First Patient in Phase 1b Study of TTI-622 in Combination With Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Written by Customer Service on April 28, 2021. Posted in Public Companies.

CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) — Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has dosed the first multiple myeloma patient with TTI-622 (SIRPα-IgG4 Fc), an investigational checkpoint inhibitor of the innate immune system, in combination with the proteasome inhibitor carfilzomib and dexamethasone. TTI-622 is a fusion protein that is designed to block the inhibitory activity of CD47, a molecule that is overexpressed by a wide variety of tumors. CD47 binds to SIRPα on macrophages and delivers a “don’t eat me” signal that inhibits the ability of macrophages to engulf and destroy cancer cells. Preclinical studies have shown that TTI-622 exhibits anti-myeloma activity as a monotherapy that...

Hiab to supply UK’s Marshall with 108 new HIAB loader cranes

Written by Customer Service on April 28, 2021. Posted in Public Companies.

HIAB XS 099 HiProHIAB XS 099 HiProHIAB XS 099 HiPro on roadHIAB XS 099 HiPro on roadHIAB XS 099 HiPro operatorHIAB XS 099 HiPro operator HIAB XS 099 HiProCARGOTEC CORPORATION, PRESS RELEASE APRIL 28 2021 AT 1:45 PM EEST Hiab, part of Cargotec, will supply the leading UK hard landscaping manufacturer Marshalls with 108 new HIAB loader cranes equipped with the connected service HiConnect™ and ProCare™ Total Repair and Maintenance contracts for eight years. The order value of EUR 4.9 million were ordered and booked in Cargotec’s quarter 1 order intake of 2021. Marshalls is a complete external landscaping products business – from planning to engineering, to guidance and delivery. From the highlands of Scotland to England’s southern tip, they offer a three-day delivery promise,...

Day: April 28, 2021

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals